OS Therapies Incorporated (OSTX)
Oxford Ledge is still expanding full research coverage of OSTX. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
OS Therapies is developing immunotherapy and antibody-drug conjugate treatments for osteosarcoma and solid tumors.
Source: 10-K (2025-12-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 8-K Entry into material agreement; Creation of direct financial obligation; 3.02; Departure/election of directors or officers; Other material event; Financial statements and exhibits 2026-07-02
- 10-Q Quarterly financial report (unaudited) 2026-05-18
- 8-K Regulation FD disclosure; Financial statements and exhibits 2026-04-30
- 8-K Entry into material agreement; Other material event; Financial statements and exhibits 2026-04-02
- 8-K Other material event; Financial statements and exhibits 2026-03-31
Source: SEC EDGAR.
Annual results
3 years of annual figures for OSTX, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | — | -$28.8M | -$0.98 |
| 2024 | — | -$8.9M | -$1.28 |
| 2023 | — | -$7.8M | -$1.46 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for OSTX. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open OSTX in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.